Information Provided By: 
Fly News Breaks for July 3, 2017
SHPG
Jul 3, 2017 | 08:58 EDT
Cantor analyst Louise Chen says that worries that Shire will lower its revenue guidance for its HAE and hemophilia franchises are overdone. She thinks that the sales of its HAE franchise will exceed expectations, as she believes that sales of its Lanadelumab drug will compensate if sales of Cinryze come in below expectations. Chen thinks that the shares are undervalued and keeps a $222 price target and an Overweight rating on the stock.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
